Development of anticeramide treatment as a novel medical countermeasure for acute effects of radiation exposure
Active Definitive Contract Awarded Last action
- Contract number
- 75N93023C00015
- Awardee
-
Ceramedix Holding, LLC UEI JLZSJRJVKJ49
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,223,612
Award facts
- Opportunity
-
- Development of Radiation/Nuclear Medical Countermeasures (MCMs) and Bio-dosimetry Devices Pre-Solicitation · 75N93021R00019 · Posted Nov 15, 2021
- Contract value 100% obligated
- $4,223,612.00 Current and potential, with all options
- Completion date 83% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 16 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- New York, NY 10022, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $964,648 | |
| Other Administrative Action | $0 | |
| Funding Only Action | $302,371 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $1,427,108 | |
| Funding Only Action | $100,000 | |
| Other Administrative Action | $0 | |
| Original award | $1,429,485 |
Show all 12
About this award
The National Institute of Allergy and Infectious Diseases awarded a $4.223 million definitive contract to Ceramedix Holding, LLC for development of anticeramide treatment as a novel medical countermeasure for acute effects of radiation exposure on July 1, 2023, under cost-plus-fixed-fee pricing with ultimate completion on June 30, 2027.
The originating pre-solicitation notice, posted November 15, 2021, sought research and development of biodosimetry approaches and medical countermeasures to assess and mitigate acute or delayed radiation injuries, with proposals required to demonstrate efficacy of medical countermeasures when administered at least 24 hours post-exposure or effectiveness of biodosimetry signatures within 30 minutes to 7 days. Place of performance is New York, NY.
Subcontractors include The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc., which has led male and female partial body irradiation mouse model development and efficacy evaluation of the lead anti-ceramide compound since June 2023, and Sloan-Kettering Institute For Cancer Research, which has characterized endothelial cell apoptosis in irradiated tissues and gastrointestinal models since June 2023.
Under Service Contract Inventory reporting, the prime invoiced $50 thousand in FY2024 (0.2 FTEs, 391 contractor hours at $127.90/hr) and $170 thousand in FY2025 (1.0 FTEs). The prime self-performed all reported hours with no subcontractor labor reported on SCI-invoiced work.
Subawards
Quick answers
Who was awarded contract 75N93023C00015?
75N93023C00015 was awarded to Ceramedix Holding, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 1, 2023.
How much is contract 75N93023C00015 worth?
The government has obligated $4,223,612 on 75N93023C00015.
Was contract 75N93023C00015 competed?
The extent of competition for 75N93023C00015 was full and open competition. The government received 16 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award